Highlights Self-Developed and Marketed Class 1 Novel Drug Orelabrutinib Selected as One of China’s 2021 Major Medical Advancements, Included in the 2022 Edition of the CSCO Malignant Hematology Treatment Guidelines admin May 15, 2022
